Compare PIPR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | LEGN |
|---|---|---|
| Founded | 1895 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2003 | 2020 |
| Metric | PIPR | LEGN |
|---|---|---|
| Price | $289.63 | $19.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $362.50 | $63.46 |
| AVG Volume (30 Days) | 188.8K | ★ 2.0M |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 54.49 | N/A |
| EPS | ★ 15.82 | N/A |
| Revenue | ★ $1,904,217,000.00 | N/A |
| Revenue This Year | $13.09 | $67.56 |
| Revenue Next Year | $14.76 | $43.20 |
| P/E Ratio | $18.48 | ★ N/A |
| Revenue Growth | ★ 24.33 | N/A |
| 52 Week Low | $202.91 | $16.24 |
| 52 Week High | $380.26 | $45.30 |
| Indicator | PIPR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 55.82 |
| Support Level | $248.90 | $16.24 |
| Resistance Level | $341.25 | $21.58 |
| Average True Range (ATR) | 11.60 | 0.91 |
| MACD | -1.56 | 0.20 |
| Stochastic Oscillator | 24.19 | 51.70 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.